Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F23%3A43925128" target="_blank" >RIV/00064173:_____/23:43925128 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/23:43925128

Result on the web

<a href="https://doi.org/10.3390/jcm12031191" target="_blank" >https://doi.org/10.3390/jcm12031191</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/jcm12031191" target="_blank" >10.3390/jcm12031191</a>

Result language

angličtina

Original language name

Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer

Original language description

Atopic dermatitis is a chronic inflammatory intensively pruritic skin disease. Patients with moderate-to-severe atopic dermatitis or with difficult-to-treat areas are candidates for systemic therapy, especially when topical therapy is inadequate. Currently, we have available not only conventional immunosuppressive systemic therapy, but also targeted biological therapy, which has shown a remarkable reduction in clinical severity with a good safety profile. Dupilumab has been approved to treat moderate-to-severe atopic dermatitis. Even though the therapy has been available for more than 3 years, there are still limited data regarding the treatment of patients with concomitant cancer. Previous immunosuppressive treatment for atopic dermatitis, such as cyclosporine or azathioprine, poses a safety risk for patients with malignant disease. We present a case series of three patients with advanced cancer and severe atopic dermatitis treated with dupilumab for an average of 17 months with a great response toward atopic dermatitis without cancer recurrence. One patient had colorectal cancer&apos; the second and the third both had cancer duplicity-colorectal and kidney cancer and penile squamous cell carcinoma with prostate cancer. Our cases suggest that dupilumab can safely control atopic dermatitis in patients with advanced cancer.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Clinical Medicine

ISSN

2077-0383

e-ISSN

2077-0383

Volume of the periodical

12

Issue of the periodical within the volume

3

Country of publishing house

CH - SWITZERLAND

Number of pages

9

Pages from-to

1191

UT code for WoS article

000931381900001

EID of the result in the Scopus database

2-s2.0-85147880863